CA2393221A1 - Procede et dispositif permettant la recirculation en circuit ferme d'un liquide cephalo-rachidien de synthese - Google Patents
Procede et dispositif permettant la recirculation en circuit ferme d'un liquide cephalo-rachidien de synthese Download PDFInfo
- Publication number
- CA2393221A1 CA2393221A1 CA002393221A CA2393221A CA2393221A1 CA 2393221 A1 CA2393221 A1 CA 2393221A1 CA 002393221 A CA002393221 A CA 002393221A CA 2393221 A CA2393221 A CA 2393221A CA 2393221 A1 CA2393221 A1 CA 2393221A1
- Authority
- CA
- Canada
- Prior art keywords
- cerebrospinal fluid
- fluid
- synthetic
- location
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001175 cerebrospinal fluid Anatomy 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims abstract description 42
- 239000012530 fluid Substances 0.000 claims abstract description 95
- 230000003750 conditioning effect Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 21
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- 230000037361 pathway Effects 0.000 claims description 16
- 238000000502 dialysis Methods 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 11
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 210000002330 subarachnoid space Anatomy 0.000 claims description 9
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 8
- 210000003703 cisterna magna Anatomy 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 210000004705 lumbosacral region Anatomy 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 4
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000003134 recirculating effect Effects 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 238000006213 oxygenation reaction Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims 2
- 238000007917 intracranial administration Methods 0.000 claims 2
- 238000010792 warming Methods 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 description 19
- 239000000839 emulsion Substances 0.000 description 15
- 208000006011 Stroke Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- -1 glucose ion Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0229—Devices operating in a closed circuit, i.e. recycling the irrigating fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
- A61M3/0216—Pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M2027/004—Implant devices for drainage of body fluids from one part of the body to another with at least a part of the circuit outside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0476—Oxygenated solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3344—Measuring or controlling pressure at the body treatment site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3653—General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M27/006—Cerebrospinal drainage; Accessories therefor, e.g. valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0201—Cassettes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0233—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
- A61M3/0254—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped
- A61M3/0258—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped by means of electric pumps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Sustainable Development (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- External Artificial Organs (AREA)
Abstract
De manière générale, cette invention concerne des procédés et des dispositifs permettant de mettre en oeuvre une recirculation en circuit fermé de liquide céphalo-rachidien (LCR), en principe d'origine synthétique, à travers les régions cérébrales et rachidiennes du corps et l'équipement de régénération et de revitalisation. Dans une réalisation préférée présentée sous forme d'une cassette, ce dispositif comprend un ensemble modulaire de matériel jetable, arrangé de préférence d'une manière permettant une utilisation rapide et aisée en cas d'urgence. Cette cassette contient de préférence tous les composants ou la plupart des composants qui composent le circuit de liquide permettant le conditionnement du LCR thérapeutique recirculé en provenance et en direction du patient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45489399A | 1999-12-03 | 1999-12-03 | |
| US09/454,893 | 1999-12-03 | ||
| PCT/US2000/042473 WO2001039819A2 (fr) | 1999-12-03 | 2000-12-01 | Procede et dispositif permettant la recirculation en circuit ferme d'un liquide cephalo-rachidien de synthese |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2393221A1 true CA2393221A1 (fr) | 2001-06-07 |
Family
ID=23806494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002393221A Abandoned CA2393221A1 (fr) | 1999-12-03 | 2000-12-01 | Procede et dispositif permettant la recirculation en circuit ferme d'un liquide cephalo-rachidien de synthese |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1235602A2 (fr) |
| JP (1) | JP2003515394A (fr) |
| KR (1) | KR20020077351A (fr) |
| CN (1) | CN1433328A (fr) |
| AU (1) | AU4512701A (fr) |
| CA (1) | CA2393221A1 (fr) |
| WO (1) | WO2001039819A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11559626B2 (en) * | 2020-04-08 | 2023-01-24 | Medtronic, Inc. | Means to treat Alzheimer's disease via flushing of brain parenchyma |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689756B2 (en) * | 2001-03-02 | 2004-02-10 | Integra Lifesciences Corporation | Treatment of neurological disease |
| CA2411569A1 (fr) * | 2002-11-12 | 2004-05-12 | Ross E. Mantle | Dispositif medical pour la recirculation extravasculaire de fluides a l'interieur de cavites corporelles dans des conditions de temperature et de pression controlees |
| US7004961B2 (en) * | 2003-01-09 | 2006-02-28 | Edward Wong | Medical device and method for temperature control and treatment of the brain and spinal cord |
| WO2007014028A1 (fr) | 2005-07-21 | 2007-02-01 | The Cleveland Clinic Foundation | Dispositifs medicaux oscillants intracraniens et leurs utilisations |
| US7699799B2 (en) | 2005-08-26 | 2010-04-20 | Ceeben Systems, Inc. | Ultrasonic material removal system for cardiopulmonary bypass and other applications |
| US20070093697A1 (en) | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
| US20180311071A1 (en) * | 2005-10-21 | 2018-11-01 | Daniel R. BURNETT | Method and apparatus for peritoneal oxygenation |
| ES2981635T3 (es) * | 2006-10-09 | 2024-10-09 | Neurofluidics Inc | Sistema de purificación de líquido cefalorraquídeo |
| US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
| US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
| US10695545B2 (en) | 2006-10-09 | 2020-06-30 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
| US10569064B2 (en) | 2013-03-13 | 2020-02-25 | Minnetronix, Inc. | Devices and methods for providing focal cooling to the brain and spinal cord |
| AU2008237177A1 (en) | 2007-04-05 | 2008-10-16 | Velomedix, Inc | Automated therapy system and method |
| US8123714B2 (en) * | 2007-06-29 | 2012-02-28 | Codman & Shurtleff, Inc. | Programmable shunt with electromechanical valve actuator |
| EP2167000A1 (fr) | 2007-07-09 | 2010-03-31 | Velomedix, Inc | Dispositifs et procédés d'hypothermie |
| WO2009058353A1 (fr) | 2007-11-02 | 2009-05-07 | The Cleveland Clinic Foundation | Dispositif pour augmenter le débit sanguin cérébral |
| WO2011114260A1 (fr) * | 2010-03-19 | 2011-09-22 | Pfizer Inc. | Système de purification de liquide céphalorachidien |
| WO2012006625A2 (fr) | 2010-07-09 | 2012-01-12 | Velomedix, Inc. | Procédé et appareil de mesure de pression |
| CN103706025A (zh) * | 2013-12-23 | 2014-04-09 | 李桂亮 | 一种埋置式蛛网膜下腔微量缓释注射器 |
| US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
| JP7166915B2 (ja) * | 2015-08-05 | 2022-11-08 | ミネトロニクス， インコーポレイテッド | 体液から物質を濾過する為の接線流フィルターシステム |
| CA3000747C (fr) * | 2015-10-06 | 2022-11-01 | Minnetronix, Inc. | Dispositifs et procedes pour apporter un refroidissement local au cerveau et a la moelle epiniere |
| ES2856599T3 (es) | 2015-12-04 | 2021-09-27 | Minnetronix Inc | Sistemas de acondicionamiento de fluido cerebrospinal |
| CA3078229A1 (fr) * | 2017-10-05 | 2019-04-11 | Minnetronix, Inc. | Systemes, catheters et procedes de traitement le long du systeme nerveux central |
| CN107993546B (zh) * | 2018-01-16 | 2019-09-06 | 西安市红会医院 | 一种脑脊液循环体外模型及脑积水体外模拟方法 |
| CN114007665B (zh) | 2019-04-11 | 2024-11-12 | 因柯利尔疗法公司 | 改善脑脊液的方法及其装置和系统 |
| CN110575573B (zh) * | 2019-09-24 | 2020-12-22 | 福建医科大学附属第一医院 | 一种用于人工脑脊液持续净化治疗的一次性管路安装系统 |
| CN115867330A (zh) * | 2020-05-11 | 2023-03-28 | 米奈特朗尼克斯神经有限公司 | 过滤匣盒及过滤系统 |
| KR20230107804A (ko) | 2020-09-29 | 2023-07-18 | 엔클리어 테라피스, 인크. | 지주막하액 관리 방법 및 시스템 |
| WO2022181126A1 (fr) * | 2021-02-26 | 2022-09-01 | テルモ株式会社 | Dispositif de traitement pour troubles cérébrovasculaires |
| WO2023003888A1 (fr) * | 2021-07-19 | 2023-01-26 | Enclear Therapies, Inc. | Plateforme de diagnostic du liquide céphalorachidien (lcr) |
| GR1010335B (el) * | 2022-02-11 | 2022-11-09 | Αναστασιος Γεωργιου Τσογκας | Συσκευη αποτροπης πνευμοκεφαλου |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981691A (en) | 1980-04-14 | 1991-01-01 | Thomas Jefferson University | Oxygenated fluorocarbon nutrient solution |
| US4686085A (en) | 1980-04-14 | 1987-08-11 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
| US4378797A (en) | 1980-04-14 | 1983-04-05 | Thomas Jefferson University | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
| WO1988008728A1 (fr) * | 1987-05-15 | 1988-11-17 | The Dis Corporation | Dispositif et procede de perfusion d'une tete d'animal |
| US5716318A (en) * | 1995-04-14 | 1998-02-10 | The University Of North Carolina At Chapel Hill | Method of treating cardiac arrest and apparatus for same |
| US5772607A (en) | 1995-06-06 | 1998-06-30 | The Nemours Foundation | Body fluid collection apparatus |
| US5823987A (en) | 1996-01-11 | 1998-10-20 | Medtronic, Inc. | Compact membrane-type blood oxygenator with concentric heat exchanger |
| AU713362B2 (en) * | 1996-03-08 | 1999-12-02 | Life Resuscitation Technologies, Inc. | Liquid ventilation method and apparatus |
| JP3803421B2 (ja) | 1996-04-26 | 2006-08-02 | 富士システムズ株式会社 | 気体交換装置 |
-
2000
- 2000-12-01 WO PCT/US2000/042473 patent/WO2001039819A2/fr not_active Ceased
- 2000-12-01 CA CA002393221A patent/CA2393221A1/fr not_active Abandoned
- 2000-12-01 JP JP2001541549A patent/JP2003515394A/ja not_active Withdrawn
- 2000-12-01 KR KR1020027007066A patent/KR20020077351A/ko not_active Withdrawn
- 2000-12-01 EP EP00992584A patent/EP1235602A2/fr not_active Withdrawn
- 2000-12-01 CN CN00818754A patent/CN1433328A/zh active Pending
- 2000-12-01 AU AU45127/01A patent/AU4512701A/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11559626B2 (en) * | 2020-04-08 | 2023-01-24 | Medtronic, Inc. | Means to treat Alzheimer's disease via flushing of brain parenchyma |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001039819A2 (fr) | 2001-06-07 |
| CN1433328A (zh) | 2003-07-30 |
| JP2003515394A (ja) | 2003-05-07 |
| AU4512701A (en) | 2001-06-12 |
| EP1235602A2 (fr) | 2002-09-04 |
| KR20020077351A (ko) | 2002-10-11 |
| WO2001039819A3 (fr) | 2002-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2393221A1 (fr) | Procede et dispositif permettant la recirculation en circuit ferme d'un liquide cephalo-rachidien de synthese | |
| US7717871B2 (en) | System and method for site specific therapy | |
| EP0088954B1 (fr) | Appareil pour utilisation dans le traitement de l'apoplexie utilisant la circulation extravasculaire d'un liquide alimentaire synthétique oxygéné pour le traitement de désordres hypoxiques et ischémiques tissulaires | |
| US4445500A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4450841A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4686085A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4378797A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4830849A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| DE69922354T2 (de) | Vorrichtung und verfahren zur ganzkörper-hyperthermiebehandlung | |
| US4446154A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4451251A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| TWI302103B (en) | Metabolic detoxification system and method | |
| US4446155A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US11219709B2 (en) | Systems and methods for treating blood | |
| US4445887A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4758431A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4445514A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4445888A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| Short et al. | Neonatal extracorporeal membrane oxygenation: a review | |
| Gislason et al. | A treatment system for implementing an extracorporeal liver assist device | |
| US11147907B2 (en) | Systems and methods for treating blood | |
| WO2023172960A1 (fr) | Système et méthode de traitement pour fœtus prématuré | |
| Touw et al. | Irrigations and Dialysis Solutions | |
| US20020179504A1 (en) | Portable hemodialyzer | |
| DE112020001865T5 (de) | Blutperfusionsvorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |